BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/9/2026 9:45:10 AM | Browse: 1 | Download: 1
 |
Received |
|
2026-01-26 00:43 |
|
Peer-Review Started |
|
2026-01-26 00:45 |
|
First Decision by Editorial Office Director |
|
2026-02-02 08:56 |
|
Return for Revision |
|
2026-02-02 08:56 |
|
Revised |
|
2026-02-11 14:30 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-04-13 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-04-13 09:36 |
|
Articles in Press |
|
2026-04-13 09:36 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-08 07:36 |
|
Publish the Manuscript Online |
|
2026-09-09 09:45 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Correspondence |
| Article Title |
Letter to the Editor: Beyond the mechanism: MiR-206 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma after incomplete radiofrequency ablation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yan Xu, Xiao-Bing Huang and Yong-Gang He |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Shapingba District, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn |
| Key Words |
MicroRNA-206; Hepatocellular carcinoma; Radiofrequency ablation; Prognostic biomarker; Nanotherapy; Precision medicine |
| Core Tip |
This commentary extends the findings from a recent article by proposing two concrete translational applications for microRNA-206 in the management of hepatocellular carcinoma: (1) As a preoperative biomarker to stratify recurrence risk before ablation; and (2) As a therapeutic agent administered locally by a nanocarrier during or after radiofrequency ablation to prevent recurrence. The potential duality of microRNA-206 could transform the standard of care for patients with high-risk hepatocellular carcinoma. |
| Publish Date |
2026-09-09 09:45 |
| Citation |
Xu Y, Huang XB, He YG. Letter to the Editor: Beyond the mechanism: MiR-206 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma after incomplete radiofrequency ablation. World J Gastrointest Oncol 2026; 18(9): 119098
|
| URL |
https://www.wjgnet.com/1948-5204/full/v18/i9/119098.htm |
| DOI |
https://doi.org/10.4251/wjgo.119098 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
